XENOPORT
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
XENOPORT
Industry:
Biotechnology Developer Platform Pharmaceutical
Founded:
1999-01-01
Address:
Santa Clara, California, United States
Country:
United States
Website Url:
http://www.xenoport.com
Total Employee:
251+
Status:
Active
Contact:
14086167210
Email Addresses:
[email protected]
Total Funding:
143.77 M USD
Technology used in webpage:
GStatic Google Static Content Register.com DNS Network Solutions Omniture SiteCatalyst Cogent Communications Edgar Online
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
GGV Capital
GGV Capital investment in Series D - Xenoport
GGV Capital
GGV Capital investment in Series C - Xenoport
Venrock
Venrock investment in Series C - Xenoport
Venrock
Venrock investment in Series B - Xenoport
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Xenoport
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Xenoport
Venrock
Venrock investment in Series A - Xenoport
Skyline Ventures
Skyline Ventures investment in Series A - Xenoport
Alejandro Zaffaroni
Alejandro Zaffaroni investment in Series A - Xenoport
CMEA Ventures
CMEA Ventures investment in Series A - Xenoport
Official Site Inspections
http://www.xenoport.com
- Host name: 104.21.112.1
- IP address: 104.21.112.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Xenoport"
Xenoport - Org Chart, Teams, Culture & Jobs - The Org
View Xenoport's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Xenoport - Crunchbase Company Profile & Funding
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological …See details»
XenoPort, Inc. | LinkedIn
XenoPort, Inc. | 2,164 followers on LinkedIn. XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product …See details»
XenoPort, Inc. Information - RocketReach
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological …See details»
XenoPort, Inc. Company Profile | Atlanta, GA - Dun & Bradstreet
Company Description: XenoPort sounds like something straight out of science fiction, but there's nothing fictional about XenoPort's job of improving drugs' ability to be absorbed by tissues in …See details»
Xenoport's Leadership Team - Team members and org chart - The …
Xenoport's Leadership Team includes Sherri Weiland and 6 others.See details»
Xenoport - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Xenoport . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of Board …See details»
Organization | XenoPort, Inc. - Purdue University
Organization Overview. First Clinical Trial. 2005 NCT00838396. First Marketed Drug. None First NDA Approval. None Last Known Activity. 2016 Timeline < Back; View all... NOW. Now; Active …See details»
XenoPort Management Team - CB Insights
Explore {XenoPort's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
CEO and Executive Team - The Org
Xenoport's CEO and Executive Team includes Anthony Macci and 5 others.See details»
XenoPort Company Profile | Management and Employees List
XenoPort Profile and History. XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential …See details»
XenoPort - Products, Competitors, Financials, Employees, …
Headquarters Location. 2000 Seaport Boulevard Suite 300. Redwood City, California, 94063, United States. 408-616-7200See details»
XenoPort 2025 Company Profile: Valuation, Investors ... - PitchBook
XenoPort General Information Description. Operator of a biopharmaceutical company intended to focus on developing and commercializing a portfolio of internally discovered product …See details»
Xenoport - Funding, Financials, Valuation & Investors - Crunchbase
XenoPort is a biopharmaceutical company that develops a portfolio of product candidates to treat neurological disorders.See details»
XenoPort Inc. - BioCentury Company Profiles - BCIQ
XenoPort Inc. - BioCentury Company Profiles for the biopharma industrySee details»
About XenoPort (XNPT) - Investing.com
This page offers an in-depth profile of XenoPort Inc, including a general overview of the company's business and key management.See details»
XenoPort Announces Plan to Focus on its Growing HORIZANT …
Oct 2, 2015 SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today a strategic shift to focus on and maximize the value of its commercial …See details»
Xenoport, Inc. | Nanotechnology Company | NPD
XenoPort, Inc. is a biopharmaceutical company focused on commercializing HORIZANT in the United States. XenoPort has entered into an agreement with the National Institute on Alcohol …See details»
XenoPort, Inc. overview - services, products, equipment
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological …See details»
Arbor buys out struggling Horizant developer XenoPort for $467M
May 23, 2016 Things went awry for XenoPort last year when XP23829, an oral psoriasis drug, came through with mixed results in a Phase II study. The company at first declared the trial a …See details»